Jivi® (antihemophilic factor [recombinant], PEGylated-aucl) – Expanded indication
May 19, 2025 - Bayer announced the FDA approval of Jivi (antihemophilic factor [recombinant], PEGylated-aucl), for use in previously treated adults and pediatric patients 7 years of age and older with hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding episodes; perioperative management of bleeding; routine prophylaxis to reduce the frequency of bleeding episodes.
Top